Association of rs1219648 in FGFR2 and rs1042522 in TP53 with Premenopausal Breast Cancer in an Iranian Azeri Population

  • Saadatian, Zahra (International Branch of Tabriz University of Medical Sciences (Aras)) ;
  • Gharesouran, Jalal (Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Ghojazadeh, Morteza (Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Ghohari-Lasaki, Sahar (Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Tarkesh-Esfahani, Najime (Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences) ;
  • Ardebili, Seyyed Mojtaba Mohaddes (International Branch of Tabriz University of Medical Sciences (Aras))
  • Published : 2014.10.11


Breast cancer is the most common cancer among women in the world. In Iran, the incidence of breast cancer is on the increase. We here studied the association of rs1219648 in FGFR2 and rs1042522 in TP53 and their interaction in development of early onset sporadic breast cancer in Iranian Azeri population to evaluate epistatic effects on the risk of mammary neoplasia. We genotyped the two polymorphisms in 100 women with early onset breast cancer and 100 healthy women by PCR-RFLP. Allele frequency differences were tested using $chi^2$-test with 95% confident intervals. Our results indicated a statistically significant association (p<0.05) between rs1219648, but not rs1042522, and risk of breast cancer. We also found that the combination of FGFR2 major genotype and TP53 hetero genotype had protective effects against breast cancer, while the hetero allele of FGFR2 in combination with the minor genotype of TP53 was associated with a high risk. This study revealed an important crosstalk between two polymorphisms in FGFR2 and TP53 in development of breast cancer. These candidates risk variants should be further evaluated in studies with a larger sample size.


  1. Cherdyntseva NV, Denisov EV, Litviakov NV, et al (2012). Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis. DNA Cell Biol, 31, 306-16.
  2. Al-Qasem A, Toulimat M, Tulbah A, et al (2012). The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett, 3, 875-8.
  3. Ayoub N, Lucas C, Kaddoumi A (2011). Genomics and pharmacogenomics of breast cancer: current knowledge and trends. Asian Pac J Cancer Prev, 12, 1127-40.
  4. Buyru N, Tigli H, Dalay N (2003). P53 codon 72 polymorphism in breast cancer. Oncol Rep, 10, 711-4.
  5. Denisov EV, Cherdyntseva NV, Litviakov NV, et al (2012). TP53 gene polymorphisms in cancer risk: the modulating effect of ageing, ethnicity and TP53 somatic abnormalities. In 'Tumor Suppressor Genes', Eds Intech, 79-110.
  6. Doosti A, Ghasemi-Dehkordi P, Davoudi N (2011). p53 codon72 polymorphism associated with breast cancer in Iranian patients. African J Pharmacy Pharmacol, 5, 1278-81.
  7. Fu F, Wang C, Huang M, et al (2012). Polymorphisms in second intron of the FGFR2 gene are associated with the risk of early-onset breast cancer in Chinese Han women. Tohoku J Exp Med, 226, 221-9.
  8. Garner I (2000). The Nucleic Acid Protocols Handbook. In Eds Humana Press, 3-7.
  9. Hu Z, Li X, Yuan R, et al (2010). Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat, 120, 705-14.
  10. Han W, Woo JH, Yu JH, et al (2011). Common genetic variants associated with breast cancer in Korean women and differential susceptibility according to intrinsic subtype. Cancer Epidemiol Biomarkers Prev, 20, 793-8.
  11. He XF, Su J, Zhang Y, et al (2011). Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat, 130, 517-29.
  12. Hosokawa K, Aharoni D, Dantes A, et al (1998). Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells. Endocrinology, 139, 4688-700.
  13. Hunter DJ, Kraft P, Jacobs KB, et al (2007). A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet, 39, 870-4.
  14. Jia C, Cai Y, Ma Y, et al (2010). Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer. Breast Cancer Res Treat, 124, 521-8.
  15. Katoh M (2008). Cancer genomics and genetics of FGFR2 (Review). Int J Oncol, 33, 233-7.
  16. Khadang B, Fattahi MJ, Talei A, et al (2007). Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet, 173, 38-42.
  17. Khan MH, Rashid H, Mansoor Q, et al (2014). Association of the rs1042522 polymorphism with increased risk of prostate adenocarcinoma in the Pakistani population and its HuGE review. Asian Pac J Cancer Prev, 15, 3973-80.
  18. Li X, Dumont P, Della Pietra A, et al (2005). The codon 47 polymorphism in p53 is functionally significant. J Biol Chem, 280, 24245-51.
  19. Marian C, Ochs-Balcom HM, Nie J, et al (2011). FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. Int J Cancer, 129, 702-12.
  20. Liang J, Chen P, Hu Z, et al (2008). Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis, 29, 2341-6.
  21. Liu CL, Hu XP, Guo WD, et al (2013). Case-control study on the fibroblast growth factor receptor 2 gene polymorphisms associated with breast cancer in Chinese Han women. J Breast Cancer, 16, 366-71.
  22. Long J, Zhang B, Signorello LB, et al (2013). Evaluating genome-wide association study-identified breast cancer risk variants in African-American women. PLoS One, 8, 58350.
  23. Ota S, Zhou ZQ, Link JM, et al (2009). The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. Hum Mol Genet, 18, 2609-21.
  24. Papadakis EN, Dokianakis DN, Spandidos DA (2000). p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun, 3, 389-92.
  25. Pouladi N, Kouhsari SM, Feizi MH, et al (2014). Lack of association of intron 3 16 bp polymorphism of TP53 with breast cancer among Iranian-Azeri patients. Asian Pac J Cancer Prev, 15, 2631-4.
  26. Prentice RL, Huang Y, Hinds DA, et al (2009). Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev, 18, 3079-85.
  27. Rahimzadeh M, Baghestani AR, Gohari MR, et al (2014). Estimation of the cure rate in Iranian breast cancer patients. Asian Pac J Cancer Prev, 15, 4839-42.
  28. Singh V, Rastogi N, Mathur N, et al (2008). Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol, 18, 48-57.
  29. Rai V (2014). The methylenetetrahydrofolate reductase C677T polymorphism and breast cancer risk in asian populations. Asian Pac J Cancer Prev, 15, 5853-60.
  30. Raskin L, Pinchev M, Arad C, et al (2008). FGFR2 is a breast cancer susceptibility gene in jewish and arab israeli populations. Cancer Epidemiol Biomarkers Prev, 17, 1060-5.
  31. Shaulian E, Resnitzky D, Shifman O, et al (1997). Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene, 15, 2717-25.
  32. Sun C, Olopade OI, Di Rienzo A (2010). rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genet Cytogenet, 197, 193-4.
  33. Suspitsin EN, Buslov KG, Grigoriev MY, et al (2003). Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer, 103, 431-3.
  34. Tarkkonen KM, Nilsson EM, Kahkonen TE, et al (2012). Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS One, 7, 49970.
  35. Turner SD, Bush WS (2011). Multivariate analysis of regulatory SNPs: empowering personal genomics by considering cisepistasis and heterogeneity. Pac Symp Biocomput, 276-87.
  36. Zhang J, Qiu LX, Wang ZH, et al (2010a). Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 124, 419-24.
  37. Zhang YX, Wang XM, Kang S, et al (2013). Common variants in the PALB2 gene confer susceptibility to breast cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 7149-54.
  38. Zhang Z, Wang M, Wu D, et al (2010b). P53 codon 72 polymorphism contributes to breast cancer risk: a metaanalysis based on 39 case-control studies. Breast Cancer Res Treat, 120, 509-17.
  39. Zhuo W, Zhang Y, Xiang Z, et al (2009). Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res, 28, 115.

Cited by

  1. 14-bp Insertion/Deletion Polymorphism of the HLA-G gene in Breast Cancer among Women from North Western Iran vol.16, pp.14, 2015,
  2. Association of p53 rs1042522, MDM2 rs2279744 and p21 rs1801270 polymorphisms with retinoblastoma risk and invasion in a Chinese population vol.5, pp.1, 2015,
  3. Genetic variants in FGFR2 and TNRC9 genes are associated with breast cancer risk in Pakistani women vol.14, pp.4, 2016,
  4. “p53 Polymorphism at Codon 72 and Breast Cancer” - Letter vol.22, pp.1, 2017,